# Phase 2 Diabetes Mellitus, Type 2 trials: 53 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials in phase 2 for Diabetes Mellitus, Type 2 that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Diabetes Mellitus, Type 2 trials: 53 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/diabetes-mellitus-type-2

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 53
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929350 | Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Diabetes Mellitus, Type 2 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929350) |
| November 10, 2026 | NCT07928661 | Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes | Universitas Sriwijaya | Phase 2 | Recruiting | Diabetes Mellitus, Type 2 | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928661) |
| November 6, 2026 | NCT07923357 | A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, T2DM | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923357) |
| November 6, 2026 | NCT07922148 | Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922148) |
| November 5, 2026 | NCT07920640 | Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Poor Glycemic Control Despite Lifestyle Intervention | Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | Phase 2 | Not yet recruiting | Diabetes Mellitus, Type 2 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920640) |
| October 22, 2026 | NCT07888426 | Tolerability and Safety of Nano-Tocotrienols | University of Malaya | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (DM) | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888426) |
| October 13, 2026 | NCT07872436 | A Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control | Vincentage Pharma Co., Ltd | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (DM) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872436) |
| September 28, 2026 | NCT07843862 | A Study of HRS-4729 Injection in Participants With Type 2 Diabetes | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843862) |
| September 24, 2026 | NCT07837934 | Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes | Tan Tock Seng Hospital | Phase 2 | Recruiting | Type 2 Diabetes Mellitus (T2DM), Atherosclerosis, Cardiovascular Diseases | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837934) |
| September 3, 2026 | NCT07801820 | Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Shanghai Minwei Biotechnology Co., Ltd | Phase 2 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801820) |
| September 1, 2026 | NCT07796477 | A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | T2DM (Type 2 Diabetes Mellitus) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796477) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| August 12, 2026 | NCT07760948 | HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide | Vanderbilt University Medical Center | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760948) |
| August 10, 2026 | NCT07755150 | A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 2 | Not yet recruiting | Type 2 Diabetes Mellitus | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755150) |
| August 5, 2026 | NCT07748208 | A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC)... | Hoffmann-La Roche | Phase 2 | Recruiting | Breast Cancer, Diabetes Type II | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748208) |
| July 1, 2026 | NCT07677891 | Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus | ProGen. Co., Ltd. | Phase 2 | Not yet recruiting | Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677891) |
| June 25, 2026 | NCT07668388 | A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | Phase 2 | Recruiting | Diabetes Mellitus, Type 2 | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668388) |
| May 14, 2026 | NCT07585630 | A1Cantus vs. Placebo | University of California, Riverside | Phase 2 | Not yet recruiting | Type 2 Diabetes | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585630) |
| May 8, 2026 | NCT07575438 | Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults | Sponsor not shown (see the record) | Phase 2 | Recruiting | Type 2 Diabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Prediabetes / Type 2 Diabetes, Obesity &... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07575438) |
| April 23, 2026 | NCT07546929 | HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes | Housey Healthcare ULC | Phase 2 | Recruiting | Type 2 Diabetes | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546929) |
| April 14, 2026 | NCT07527650 | Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus | Hanmi Pharmaceutical Company Limited | Phase 2 | Recruiting | Type 2 Diabetes Mellitus, T2DM | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527650) |
| March 31, 2026 | NCT07502508 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based... | Biomea Fusion Inc. | Phase 2 | Recruiting | Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502508) |
| February 19, 2026 | NCT07421518 | Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors | AdventHealth Translational Research Institute | Phase 2 | Not yet recruiting | Type 1 Diabetes, Type 2 Diabetes | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421518) |
| February 17, 2026 | NCT07415954 | A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Novo Nordisk A/S | Phase 2 | Recruiting | Diabetes Mellitus, Type 2 | 270 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07415954) |
| February 4, 2026 | NCT07387003 | Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes | Gan & Lee Pharmaceuticals. | Phase 2 | Not yet recruiting | Type 2 Diabetes (T2DM) | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07387003) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 2 |
| Beijing Supreme Life Pharmaceutical Technology Co., Ltd. | 2 |
| ProGen. Co., Ltd. | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| Sparrow Pharmaceuticals | 1 |
| Global Institute of Stem Cell Therapy and Research | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 1 |
| [Shenzhen Salubris Pharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/shenzhen-salubris-pharmaceuticals-co-ltd) | 1 |
| Vanderbilt University Medical Center | 1 |
| University of Malaya | 1 |
| Medical College of Wisconsin | 1 |
| University of Leeds | 1 |
| University of California, San Diego | 1 |
| Housey Healthcare ULC | 1 |
| University of California, Los Angeles | 1 |
| Vincentage Pharma Co., Ltd | 1 |
| Chinese University of Hong Kong | 1 |
| University Health Network, Toronto | 1 |
| [Fujian Shengdi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd) | 1 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | 1 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 1 |
| University of California, Riverside | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| China | 12 |
| Australia | 4 |
| Poland | 4 |
| South Korea | 3 |
| Germany | 3 |
| Hungary | 3 |
| Spain | 3 |
| Canada | 3 |
| Puerto Rico | 3 |
| Slovakia | 2 |
| United Kingdom | 2 |
| Switzerland | 2 |
| Japan | 2 |
| Indonesia | 2 |
| Malaysia | 1 |
| Romania | 1 |
| Hong Kong | 1 |
| Belgium | 1 |
| France | 1 |
| Croatia | 1 |
| Portugal | 1 |
| Thailand | 1 |
| Argentina | 1 |
| India | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hepatology practices in the United States](https://specstream.ai/data/businesses/hepatology-practices/united-states)
- [Printing companies in the United States](https://specstream.ai/data/businesses/printing-companies/united-states)
- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
- [Egyptian restaurants in the United States](https://specstream.ai/data/businesses/egyptian-restaurants/united-states)
- [Medical service organizations in the United States](https://specstream.ai/data/businesses/medical-service-organizations/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
